TeGenero AG
Industry
- Pharmaceuticals
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
Latest on TeGenero AG
2016 was a year of political surprises of such international impact that their aftershocks will be felt by the pharma and biotech industries for many years. But, for Scrip ’s readers, more parochial
By their very nature, crises are unexpected, which makes the planning and management involved all the more important when defining a company strategy in the modern age of 24-hour social media. The Ins
A newspaper has launched a campaign in the UK to review the way that clinical trials are carried out in adolescents. It follows the death of a 17-year-old girl with Ewing’s sarcoma who was rejected fo
FDA Commissioner Margaret Hamburg is pushing hard for more openness from the industry to release information to potential competitors on the reasons why drugs fail. Speaking at the Financial Times P